Weight loss at the time of GLP-1 discontinuation was 10.1% overall, 9.7% for those with T2D, and 11.1% for those without.

No drugs are specifically indicated for MASLD, but the FDA has granted accelerated approval to two drugs for non-cirrhotic ...

The Trump administration has directed visa officers to consider obesity and other chronic health conditions when deciding ...

The ongoing saga around federal nutrition aid is yet another moment that highlights how food insecurity can lead to long-term ...

A study published Wednesday reports "significant" disparities in the risk of dementia for lower income and non-white ...

The medications aren’t just for diabetes and obesity, but they also aren’t for every ailment.

A new directive by President Donald Trump’s administration could make it more difficult for foreigners to visit or live in ...

Impaired kidney function was also identified as a key risk factor for heart disease, contributing to about 12% of global ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

The Academy of Nutrition and Dietetics released a new position paper, "The Effectiveness of Medical Nutrition Therapy in Prevention and Treatment of Chronic Disease," published in the Journal of the ...

A sweeping global study reveals that chronic kidney disease now affects nearly 800 million people and has become one of the world’s top 10 causes of death. A new global analysis reveals that more ...